Catalyst
Monitor the FDA's decision on the sBLA by October 9, 2026, and subsequent regulatory filings with the EMA.
Date
June 11, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.